Relay Therapeutics, Inc. (RLAY) Earnings Call Transcripts
Relay Therapeutics, Inc.'s Latest Earnings Call - April 27, 2026
In the first quarter of fiscal year 2026, Relay Therapeutics provided a significant update on its lead program, zovegalisib, focusing on its potential in frontline breast cancer treatment. The company announced a pivotal trial, ReDiscover 2, which is currently recruiting patients and aims to differentiate zovegalisib from existing therapies. Management expressed confidence in the triplet therapy's efficacy and tolerability, with a reported overall response rate (ORR) of 44% in heavily pretreated patients, suggesting strong potential as they move into earlier treatment lines. No specific revenue or earnings figures were disclosed, and guidance for future trials was maintained with plans to initiate a Phase III trial in early 2027.
Reported metrics
| Metric | Value |
|---|---|
| Overall Response Rate (ORR) | 44% (positive) |
| Grade 3 or Higher Treatment-Related Adverse Events | 40% (positive) |
| Patient Retention Rate | 77% (positive) |
| Phase III Trial Start Date | Early 2027 (neutral) |
| Supply Agreement with Pfizer | Extended (positive) |
Guidance from management
Management maintained guidance for the initiation of the Phase III trial in early 2027, emphasizing the importance of regulatory interactions to finalize the trial design and dosing strategy.
What management said
Yes. Thanks for the question, Brad. Yes, there are limitations for both us and Pfizer moving forward in the near term with other PI3K or selective CDK4 molecules into a Phase III trial. We believe that we will definitely be first to market with this selective selective approach.
Yes. So what we've seen in [ rash ] has been primarily low grade, well-managed with antihistamines. It is something that we've not seen at high rates before with zovega. And I think we'll wait to see more robust disclosures from a term including the upcoming [ IV Light 1 ] disclosure to understand what the potential contribution of atirmo could be. We are in later line patients. We are in patients who have seen pri...
What analysts pressed on
Analysts expressed concerns regarding the competitive landscape and the potential for Pfizer to supply atirmociclib to other companies. There were also questions about the durability of treatment responses and how Relay's triplet therapy would compare against existing therapies in terms of efficacy and tolerability.
Main topics on the call
- Triplet Therapy Efficacy — Management reported an overall response rate (ORR) of 44% for the zovega-atirmo-fulvestrant triplet in a heavily pretreated patient population, which approaches the ORR of existing first-line therapies. They noted, "we e...
- Regulatory Progress — Relay plans to initiate its Phase III trial in early 2027, pending regulatory feedback. Management stated, "we will conduct regulatory interactions to confirm the Phase III design and dose and rapidly prepare to start th...
- Supply Agreement with Pfizer — The company announced an extended supply agreement with Pfizer for atirmociclib, which will be used in the upcoming Phase III trial. This agreement is seen as a strategic advantage, with management asserting, "we believe...
- Tolerability Profile — Management highlighted a favorable tolerability profile for the triplet regimen, with only 40% of patients experiencing Grade 3 or higher treatment-related adverse events. They emphasized, "tolerability is key as the obj...
Read the full Relay Therapeutics, Inc. transcript (April 27, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Relay Therapeutics, Inc.
Relay Therapeutics, Inc. (RLAY) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 28 calls on record spanning October 8, 2021 to June 8, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 28 Relay Therapeutics, Inc. earnings call transcripts on record, spanning October 8, 2021 to June 8, 2026. Based on this history, Relay Therapeutics, Inc. reports quarterly. The most recent call on file is dated June 8, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- RLAY
- Exchange
- NasdaqGM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 28
- First call
- October 8, 2021
- Most recent
- June 8, 2026
- Reporting cadence
- quarterly